Can a softer chemo regimen spare older breast cancer patients?

NCT ID NCT03858322

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This pilot trial is testing whether a lower-toxicity chemotherapy combination can be a feasible option for adults aged 70 and older with HER2-negative breast cancer. The study aims to see how well older patients tolerate the treatment and whether they can complete the planned course. It compares different chemotherapy drugs (paclitaxel, cyclophosphamide, and carboplatin) to find a gentler yet effective approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of chemotherapy drugs (paclitaxel, cyclophosphamide, and carboplatin) given at lower toxicity levels
What this could lead to: If successful, this could lead to more tolerable chemotherapy regimens for older adults with breast cancer, improving their quality of life during treatment.
What could go wrong: This is a small pilot study, so results may not apply broadly. The lower-dose chemo might be less effective at preventing cancer recurrence, and side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

City of Hope National Medical Center

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center

Milford, Massachusetts, 01757, United States
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
Novant Health Oncology Specialists

Winston-Salem, North Carolina, 27103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.